US President Trump’s proposed tariffs on imported generic drugs will not immediately affect Indian drugmakers. Indian companies export significant generic medicines to the United States market. The proposed tariffs are set to begin in 2028, offering a two-year window. This lead time allows Indian firms to explore alternative export markets and adapt. American patients and insurers will likely face increased healthcare costs after tariffs are imposed.